The eukaryotic translation initiation factor (eIF) 3a is described in various tumor entities as potential tumor marker involved in development and progression of cancer. eIF3a is the largest subunit of the eIF3 complex, a key functional entity in 80S establishment and translation initiation. We hypothesize that eIF3a is more a specific than global translation initiator and involved in signalling pathways that are frequently targeted in UBC therapy.
eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation.
Specimen part, Cell line, Treatment
View SamplesTumor infiltrating neutrophils (TAN) have been shown to exert both pro- and anti-tumoral activities and their recruitment and polarization are triggered by tumor-derived signals. Resident mesenchymal stromal cells (MSC) could contribute to tumor-supportive cell niche and have been shown to display tumor-specific transcriptomic, phenotypic, and functional features compared to normal tissue. In our study, we investigate whether these two cell subsets establish a bidirectional crosstalk in the context of B-cell lymphoma.
Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas.
Treatment
View SamplesThis SuperSeries is composed of the SubSeries listed below.
MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.
Sex, Disease
View SamplesThe purpose of this study was to investigate the expression dynamics of mRNAs and microRNAs in response to subcutaneous IFN-beta-1b treatment (Betaferon, 250 g every other day) in patients with clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS) or relapsing-remitting type of the disease (RRMS).
MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.
Sex, Disease
View SamplesWe analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS).
Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis.
Sex, Subject
View SamplesWe analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS).
Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis.
Sex, Subject
View SamplesWe analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS).
High-Resolution Expression Profiling of Peripheral Blood CD8<sup>+</sup> Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution.
Sex, Subject
View SamplesWe analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS).
High-Resolution Expression Profiling of Peripheral Blood CD8<sup>+</sup> Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution.
Sex, Subject
View SamplesThis SuperSeries is composed of the SubSeries listed below.
Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
Sex, Subject
View SamplesWe used DNA microarrays (HG-U95Av2 GeneChips) to determine gene expression profiles for kidney biopsies and peripheral blood lymphocytes (PBLs) in transplant patients. Sample classes include kidney biopsies and PBLs from patients with 1) healthy normal donor kidneys, 2) well-functioning transplants with no clinical evidence of rejection, 3) kidneys undergoing acute rejection, and 4) transplants with renal dysfunction without rejection. Nomenclature for samples is as follows: 1) all sample names include either BX or PBL to indicate that they were derived from biopsies or PBLs respectively, 2) C indicates samples from healthy normal donors, 3) TX indicates samples from patients with well-functioning transplants with no clinical evidence of rejection, 3) AR indicates samples from transplant patients with kidneys undergoing acute rejection, 4) NR indicates samples from transplant patients with renal dysfunction without rejection.
Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes.
No sample metadata fields
View Samples